Expert Interview
Discussing Guardant Health's new liquid biopsy, SHIELD, in detecting colorectal cancer
Ticker(s): GHInstitution: Yale University
- Academic hepatologist, Associate Professor of Medicine (Digestive Diseases) and Director, Yale Viral Hepatitis Program.
- Treats patients with chronic liver diseases including the entire spectrum from cirrhosis, liver failure, and post-transplant; Approximately 5-10% of his patients have chronic pruritus symptoms, 200 patients with biopsy-proven NASH and a larger cohort of NAFLD, and 70 patients with PBC/PSC.
- Has served on the national steering committees for large observational cohort studies for liver disease and has published over 100 papers in the area of GI and liver diseases.
Do you think the FDA will approve this based on the data so far?
On a scale of one to 10, how excited are you for this test?
As far as colon cancer screenings go, are you conducting those personally as a gastroenterologist, and how often, on a monthly basis?
Would you say that most of your patients are up-to-date with recommended screenings, or do you find that some patients are still non-compliant, or don't really do as you would like?
Is colonoscopy still the gold standard in your mind?
Is Cologuard something that you are comfortable with recommending to a patient?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
